Skip to main content
Top
Published in: Virology Journal 1/2009

Open Access 01-12-2009 | Research

Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland

Authors: John F Menton, Suzanne M Cremin, Lydie Canier, Mary Horgan, Liam J Fanning

Published in: Virology Journal | Issue 1/2009

Login to get access

Abstract

Background

Human papillomavirus (HPV) causes cervical cancer and external genital warts. The purpose of this study is to document the genotype distribution of HPV in females aged between 18 and 34 who self-referred to an STI clinic with visible external genital warts (EGW). Scrapings were taken from visible external genital warts (EGW). These scrapings were analysed by PCR for the presence of HPV DNA. Positive samples were then genotyped by means of a commercially available assay (LiPA). A comparison of genotyping results determined by the LiPA assay and direct amplicon DNA sequencing was also performed.

Results

Ninety-two patients out of 105 samples (88%) had detectable levels of HPV DNA. The majority of individuals with EGW (66%) showed the presence of two or more genotypes. The most common HPV genotypes present in the study population were HPV-6, HPV-11, HPV-16, HPV-18, HPV-33 and HPV-53. Potential effects of vaccination on HPV molecular epidemiology indicate that 40% of the patients could have been protected from the high risk genotypes HPV-16 and HPV-18.

Conclusion

This is the first report of the molecular epidemiology of external genital warts in women aged between 18 and 34 from Ireland based on results from a LiPA assay. The study shows that most individuals are infected with multiple genotypes including those with high oncogenic potential and that the newly available HPV vaccines could have a significant impact on prevalence of the most common HPV genotypes in this study population.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006,24(Suppl 3):S3/1-10. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006,24(Suppl 3):S3/1-10.
3.
go back to reference Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH: Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37: 3316-3322.PubMedCentralPubMed Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH: Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37: 3316-3322.PubMedCentralPubMed
4.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-FCrossRefPubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-FCrossRefPubMed
5.
go back to reference Meyer T, Stockfleth E: Classification of human papillomavirus. N Engl J Med 2003, 348: 2040-2041. author reply 2040–2041. 10.1056/NEJM200305153482022CrossRefPubMed Meyer T, Stockfleth E: Classification of human papillomavirus. N Engl J Med 2003, 348: 2040-2041. author reply 2040–2041. 10.1056/NEJM200305153482022CrossRefPubMed
6.
go back to reference Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23: 1107-1122. 10.2165/00019053-200523110-00004CrossRefPubMed Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23: 1107-1122. 10.2165/00019053-200523110-00004CrossRefPubMed
7.
go back to reference Herzog TJ: New approaches for the management of cervical cancer. Gynecol Oncol 2003, 90: S22-27. 10.1016/S0090-8258(03)00466-9CrossRefPubMed Herzog TJ: New approaches for the management of cervical cancer. Gynecol Oncol 2003, 90: S22-27. 10.1016/S0090-8258(03)00466-9CrossRefPubMed
9.
go back to reference Bryan JT: Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007, 25: 3001-3006. 10.1016/j.vaccine.2007.01.013CrossRefPubMed Bryan JT: Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007, 25: 3001-3006. 10.1016/j.vaccine.2007.01.013CrossRefPubMed
10.
go back to reference Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367: 1247-1255. 10.1016/S0140-6736(06)68439-0CrossRefPubMed Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367: 1247-1255. 10.1016/S0140-6736(06)68439-0CrossRefPubMed
11.
go back to reference Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38: 357-361.PubMedCentralPubMed Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38: 357-361.PubMedCentralPubMed
12.
go back to reference Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefevre P, Kaufman L, Garbar C: Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol 2007, 45: 928-934. 10.1128/JCM.02098-06PubMedCentralCrossRefPubMed Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefevre P, Kaufman L, Garbar C: Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol 2007, 45: 928-934. 10.1128/JCM.02098-06PubMedCentralCrossRefPubMed
13.
go back to reference Matsukura T, Sugase M: Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer 2008, 18: 1042-1050. 10.1111/j.1525-1438.2007.01157.xCrossRefPubMed Matsukura T, Sugase M: Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer 2008, 18: 1042-1050. 10.1111/j.1525-1438.2007.01157.xCrossRefPubMed
15.
16.
go back to reference Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369: 1693-1702. 10.1016/S0140-6736(07)60777-6CrossRefPubMed Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369: 1693-1702. 10.1016/S0140-6736(07)60777-6CrossRefPubMed
17.
go back to reference Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348: 518-527. 10.1056/NEJMoa021641CrossRefPubMed Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348: 518-527. 10.1056/NEJMoa021641CrossRefPubMed
Metadata
Title
Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland
Authors
John F Menton
Suzanne M Cremin
Lydie Canier
Mary Horgan
Liam J Fanning
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2009
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-6-112

Other articles of this Issue 1/2009

Virology Journal 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.